Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TG-1801 Alone or with Ublituximab in B-Cell Lymphoma or CLL
NCT04806035Phase 1Terminated
- Sponsor
- TG Therapeutics, Inc.
- Start
- Apr 2021
- Primary completion
- Jun 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of NI-1701 in B cell lymphoma and chronic lymphocytic leukemia (CLL) (3 arms), sponsored by TG Therapeutics, Inc. Primary endpoint: Recommended Phase 2 Dose up to 24 months. Started Apr 2021; status: terminated.
02
Drugs
NI-1701
03
Conditions
B cell lymphomachronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04806035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04806035.